10-Q · May 14, 2026
Bone Biologics reported a continued net loss in Q1 2026, with net losses improving by 24.69% YOY, totaling $765,988. Operating expenses decreased significantly by 22.48% primarily due to lower R&D spending, while…
Earnings analysis · 10-Q
BBLG earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q extract does not include income statement, balance sheet, cash flow, segment, or MD&A operating results, so revenue, margin, EPS, liquidity, and free-cash-flow trends cannot be assessed. Disclosure…
Read full summary
The provided 10-Q extract does not include income statement, balance sheet, cash flow, segment, or MD&A operating results, so revenue, margin, EPS, liquidity, and free-cash-flow trends cannot be assessed. Disclosure controls were deemed effective as of June 30, 2026, with no material internal-control changes reported for the quarter. The most material filing update is the potential Nasdaq delisting risk tied to a $5 million market-value requirement and a 30-business-day compliance period, although the rule was stayed on July 29, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remain effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No material control changes
The company reported no changes during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
No material legal proceedings disclosed
The company stated that it is not presently a party to legal proceedings that would have a material adverse effect on its business, results of operations, financial condition or cash flows.
What to watch
-
Potential Nasdaq delisting
A new Nasdaq continued-listing rule approved on July 22, 2026 would require at least $5 million of market value of listed securities. The company stated it would not comply if the rule took effect; failure to meet the requirement for 30 consecutive business days could result in suspension and immediate delisting. The SEC stay announced July 29, 2026 temporarily paused the rule pending review.
Management's outlook
The provided 10-Q extract contains no quantitative revenue or EPS outlook. The filing refers to the 2025 Form 10-K and current MD&A for additional discussion, but no numeric guidance is disclosed in the provided text.
Earlier filings 4
10-K · March 2, 2026
Bone Biologics is a clinical-stage orthobiologics company focused on developing NELL-1/DBM (NB1) for lumbar spinal fusion. The company has advanced from pivotal animal work (37.5% increased fusion frequency at 26 weeks)…
10-Q · August 9, 2024
Bone Biologics reported no revenue for the quarter (Revenues $0) and materially reduced operating spending, producing a smaller net loss of $783,733 (Q2 2024) versus $1,769,238 (Q2 2023). Cash declined to $2,332,068 at…
10-Q · May 14, 2024
Bone Biologics (BBLG) reported Q1 net loss of $865,970 (loss per share $1.31) versus a loss of $3,709,899 (loss per share $55.20) in Q1 2023 — a material reduction in loss driven by a sharp decline in operating…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.